Zevra Therapeutics Inc. (ZVRA)
7.17
-0.03 (-0.42%)
At close: Apr 28, 2025, 1:38 PM
-0.42% (1D)
| Bid | 7.16 |
| Market Cap | 392.32M |
| Revenue (ttm) | 23.61M |
| Net Income (ttm) | -105.51M |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -3.15 |
| Forward PE | 11.15 |
| Analyst | Strong Buy |
| Ask | 7.17 |
| Volume | 94,247 |
| Avg. Volume (20D) | 466,390 |
| Open | 7.22 |
| Previous Close | 7.20 |
| Day's Range | 7.14 - 7.28 |
| 52-Week Range | 4.20 - 9.76 |
| Beta | 1.94 |
About ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipe...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2015
Employees 59
Stock Exchange NASDAQ
Ticker Symbol ZVRA
Website https://zevra.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 199.65% from the latest price.
Stock ForecastsNext Earnings Release
Zevra Therapeutics Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.41%
Zevra Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+8.19%
Zevra Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $20.
